Sol-Gel Technologies Ltd. (SLGL)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sol-Gel Technologies Ltd. ("Sol-Gel" or "the Company") (NASDAQ: SLGL). The investigation concerns whether Sol-Gel and certain of its officers and/or directors have violated federal securities laws.


On April 27, 2021, Sol-Gel issued a press release “announc[ing] an update regarding the U.S. Food and Drug Administration (FDA) approval process for EPSOLAY® (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults.”  The press release stated, in relevant part: “In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for EPSOLAY is April 26, 2021.  Subsequently, the COVID-19 pandemic restricted the FDA’s ability to conduct pre-approval inspections.  In our most recent written communication with the FDA regarding EPSOLAY, the final content of the labeling was discussed and agreed to.  As of today, Sol-Gel has received no notification from the FDA, but did receive email confirmation that that action on the NDA for EPSOLAY could not be taken since a pre-approval inspection of the production site of EPSOLAY still needs to be conducted.”  On this news, Sol-Gel’s stock price fell sharply during intraday trading on April 27, 2021.


If you are aware of any facts relating to this investigation, or purchased Sol-Gel shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.